<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hemorrhagic transformation (HT) and <z:hpo ids='HP_0002181'>brain edema</z:hpo> are life-threatening complications of recombinant tissue plasminogen activator (rt-PA)-induced reperfusion after <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The risk of HT limits the therapeutic window for reperfusion to 3 h after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Pre-treatment with matrix metalloproteinase (MMP) inhibitors reduces HT and <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>However, whether a delayed therapeutic intervention would be beneficial is unknown </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, 215 male Sprague-Dawley rats were subjected to embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> and 75 rats were included in the final analysis </plain></SENT>
<SENT sid="5" pm="."><plain>The animals were treated with the MMP inhibitor p-aminobenzoyl-gly-pro<z:chebi fb="0" ids="30005">-D-leu</z:chebi><z:chebi fb="2" ids="29949">-D-ala</z:chebi>-hydroxamate before or after 3 or 6 h of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Animals were monitored for reperfusion and received rt-PA 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The results at 24 h showed that MMP inhibition 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> significantly decreased the degree of <z:hpo ids='HP_0002181'>brain edema</z:hpo> (17% of hemispheric enlargement in the treated group versus 24% in controls, P=0.018), reduced the risk (OR=0.163; 95% CI: 0.029 to 0.953) and gravity (0.09 versus 0.19 mg of parenchymal <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, P=0.02) of <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo>, and improved neurological outcome (20% of the treated animals had a slight deficit; <z:hpo ids='HP_0000001'>all</z:hpo> of the controls had a bad outcome, P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Delaying MMP inhibition to 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> restricted the beneficial role of the treatment to a reduction in the risk of parenchymal <z:mp ids='MP_0001914'>hemorrhage</z:mp> (OR=0.242; 95% CI: 0.060 to 0.989) </plain></SENT>
<SENT sid="9" pm="."><plain>Our results confirm the involvement of MMPs in HT and support the possibility of extending the therapeutic window for thrombolysis in <z:hpo ids='HP_0001297'>stroke</z:hpo> by administering a broad-spectrum MMP inhibitor after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>